dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Colle, Raphael |
dc.contributor.author | Lonardi, Sara |
dc.contributor.author | Cachanado, Marine |
dc.contributor.author | overman, michael |
dc.contributor.author | Elez, Elena |
dc.contributor.author | Fakih, Marwan |
dc.date.accessioned | 2023-09-26T10:48:20Z |
dc.date.available | 2023-09-26T10:48:20Z |
dc.date.issued | 2023-09-07 |
dc.identifier.citation | Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, et al. BRAFV600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 Sep 7;28(9):771–79. |
dc.identifier.issn | 1083-7159 |
dc.identifier.uri | https://hdl.handle.net/11351/10351 |
dc.description | Mutació BRAF; Síndrome de Lynch; Inhibidors del punt de control immunològic |
dc.description.sponsorship | This research did not receive any specific grant from funding of industry; partially funded by IOVIRCCS 5x1000 Grant, Missoni Project, code BIGID219ZAGO, and by Association de Recherche en Oncologie Saint-Antoine (AROSAT). |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | The Oncologist;28(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Anomalies cromosòmiques |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Còlon - Càncer - Aspectes genètics |
dc.subject | Recte - Càncer - Aspectes genètics |
dc.subject.mesh | Colorectal Neoplasms, Hereditary Nonpolyposis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /therapeutic use |
dc.subject.mesh | Mutation |
dc.title | BRAFV600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/oncolo/oyad082 |
dc.subject.decs | neoplasias colorrectales hereditarias sin poliposis |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /uso terapéutico |
dc.subject.decs | mutación |
dc.relation.publishversion | https://doi.org/10.1093/oncolo/oyad082 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Colle R] Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France. Sorbonne University, SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France. Sorbonne University, Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, St Antoine Hospital, Paris, France. [Lonardi S] Oncology Department, Istituto Oncologico Veneto IOV-IRCSS, Padua, Italy. [Cachanado M] Sorbonne University, Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, St Antoine Hospital, Paris, France. [Overman MJ] Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Elez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fakih M] Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA |
dc.identifier.pmid | 37023721 |
dc.identifier.wos | 000963952600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |